This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in RSCM-FKUI
This study aims to Assess the effectiveness and safety of intradermal concentrated secretome injection therapy, triple combination cream, and intradermal tranexamic acid injection in melasma patients, determine the quality of life profile of melasma patients after triple combination cream therapy in melasma therapy, and determine SOD levels in melasma patients.
This research will be attended by 90 research subjects
Women diagnosed with melasma.
Women without melasma and have areas of skin that are clinically free of lesions for SP control.
30-60 years old.
Fitzpatrick skin type IV-V.
Pregnant and breastfeeding women.
Currently using hormonal contraception or have ever used contraception hormones in the last 6 months.
Using topical therapy for melasma, for example corticosteroids, tretinoin, hydroquinone, and other therapies that whiten or brighten the skin in the last 2 weeks.
Using topical triple combination cream therapy for at least 3 months and did not show significant improvement
Dr.dr.Irma Bernadette, SpKK (K)
Lead sponsor
Indonesia University
Sponsor institution